Synovial Fluid Mediated Aggregation of Clinical Strains of Four Enterobacterial Species.
Aggregates
Biofilm
Enterobacteria
Prosthetic joint infection
Rapid screen
Septic arthritis
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
17
8
2020
medline:
15
4
2021
entrez:
16
8
2020
Statut:
ppublish
Résumé
Septic arthritis and prosthetic joint infection (PJI) are conditions commonly associated with Gram-positive cocci, however, a drastic increase in cases derived from enterobacterial species has been observed. Recently it has been reported by multiple groups that staphylococci rapidly form free-floating aggregates in the presence of synovial fluid. These aggregates are comparatively more resistant to antimicrobial challenge than their planktonic counterparts, and thus may play a role in the pathogenesis of joint infection. While staphylococcal aggregates have been the primary focus of interest in the field, it is unclear just how widespread synovial fluid mediated aggregation (SFMA) is in Gram negative enterobacteria (GNE). Through this work we have evaluated SFMA in clinical GNE isolated from PJIs. Two PJI clinical strains each of Enterobacter cloacae, Escherichia coli, Klebsiella pneumonia and Proteus mirabilis strains representing a range of antibiotic susceptibilities were exposed to 10% bovine synovial fluid supernatant (BSF) using a relatively simple, quick semi-quantitative method using an imaging plate reader. BSF stimulated aggregation within 0.5 h both strains of E. cloacae and P. mirabilis and one strain of E.coli. In one strain of P. mirabilis and E.coli, the size of the aggregates significantly increased from 0.5 to 2 h exposure. In contrast, neither K. pneumoniae strain aggregated in BSF. These preliminary findings show that aggregation can occur quickly in GNE, but the extent appears strain and species specific. Further work is required to assess the impact of SFMA on antibiotic tolerance, host innate immunity and the establishment of biofilms.
Identifiants
pubmed: 32797406
doi: 10.1007/5584_2020_573
pmc: PMC7882635
mid: NIHMS1625274
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
81-90Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM124436
Pays : United States
Références
JAMA. 2007 Apr 4;297(13):1478-88
pubmed: 17405973
Clin Microbiol Infect. 2016 Aug;22(8):732.e1-8
pubmed: 27181408
Clin Microbiol Infect. 2014 Nov;20(11):O911-9
pubmed: 24766536
J Infect Dis. 2015 Feb 15;211(4):641-50
pubmed: 25214518
Infect Dis Clin North Am. 2017 Dec;31(4):715-729
pubmed: 29079156
Ann R Coll Surg Engl. 2014 Mar;96(2):e11-2
pubmed: 24780657
PLoS One. 2020 Apr 17;15(4):e0231791
pubmed: 32302361
Singapore Med J. 2013 Aug;54(8):e164-8
pubmed: 24005465
Nature. 2013 Sep 5;501(7465):52-7
pubmed: 23965627
Clin Microbiol Rev. 2002 Oct;15(4):527-44
pubmed: 12364368
Arthritis Rheum. 1997 May;40(5):884-92
pubmed: 9153550
PLoS One. 2019 Aug 15;14(8):e0221012
pubmed: 31415623
Infect Immun. 2016 May 24;84(6):1917-1929
pubmed: 27068096
N Engl J Med. 1985 Mar 21;312(12):764-71
pubmed: 3883171
J Infect Dis. 2015 Jul 15;212(2):335-6
pubmed: 25712965
N Engl J Med. 2009 Aug 20;361(8):787-94
pubmed: 19692690
Clin Microbiol Rev. 2014 Apr;27(2):302-45
pubmed: 24696437
Infect Dis Clin North Am. 2017 Jun;31(2):203-218
pubmed: 28366221
J Vis Exp. 2016 Nov 17;(117):
pubmed: 27911396
Lancet Infect Dis. 2020 Mar;20(3):341-349
pubmed: 31862240
Mol Ther. 2017 Sep 6;25(9):2104-2116
pubmed: 28750737
Clin Infect Dis. 2013 Jan;56(1):e1-e25
pubmed: 23223583
J Med Assoc Thai. 1990 Nov;73(11):615-23
pubmed: 2283490
mBio. 2016 Mar 22;7(2):e00237
pubmed: 27006463
Clin Microbiol Rev. 2002 Apr;15(2):167-93
pubmed: 11932229